论文部分内容阅读
为探讨新生儿缺氧缺血性脑病（ＨＩＥ）血浆β－内啡肽（β－ＥＰ）改变及观察纳络酮治疗ＨＩＥ的临床疗效，采用放射免疫法测定３８例ＨＩＥ患儿分别于生后７２ｈ内和７～１０ｄ血浆β－ＥＰ浓度并设对照组；并将３８例患儿随机分为纳络酮治疗组和非纳络酮治疗组。发现：３８例ＨＩＥ患儿早期血浆β－ＥＰ水平较２５例正常新生儿显著增高（Ｐ＜００５），恢复期与正常新生儿比较无差异（Ｐ＞００５）。纳络酮治疗组与非纳络酮组治疗前后血浆β－ＥＰ浓度差值比较未见差异，但纳络酮组能使病程缩短及重症患儿临床症状迅速好转。提示β－ＥＰ参与ＨＩＥ的病理生理过程，以及纳络酮对ＨＩＥ仍有一定治疗作用。
To investigate the changes of plasma β-EP in neonates with hypoxic-ischemic encephalopathy (HIE) and to observe the clinical efficacy of naloxone in the treatment of HIE, radioimmunoassay was used to detect 38 HIE children after birth 72h and 7 ~ 10d plasma β-EP concentration and control group; and 38 patients were randomly divided into naloxone treatment group and non-naloxone treatment group. The results showed that plasma β-EP levels in 38 HIE children were significantly higher than those in 25 normal newborns (P <005). There was no difference between the two groups (P> 0.05). Naloxone treatment group and non-naloxone group before and after treatment, plasma β-EP concentration difference was no difference, but naloxone group can shorten the course of the disease and severe symptoms in children with rapid improvement. It suggested that β-EP participates in the pathophysiological process of HIE, and Naloxone still has a certain therapeutic effect on HIE.